Previous 10 | Next 10 |
LOS ANGELES, CA / ACCESSWIRE / August 31, 2020 / LD Micro today announced the final list of companies slated to present at the upcoming LD 500, taking place September 1st-4th, 2020, exclusively online. Registration details and the company schedule can be seen here: https://ld500.ldmicro.co...
Nortech Systems NSYS +60% on completing sale-leaseback. More news on: Medigus Ltd., China Liberal Education Holdings Limited, Pacific Ethanol, Inc., Stocks on the move, , Read more ...
SEATTLE, Aug. 26, 2020 (GLOBE NEWSWIRE) -- Atossa Therapeutics, Inc. (Nasdaq: ATOS), a clinical-stage biopharmaceutical company seeking to discover and develop innovative medicines in areas of significant unmet medical need with a current focus on breast cancer and COVID-19, today announces...
Atossa Therapeutics ( ATOS -0.5% ) announces that the first cohort of eight healthy volunteers in its Phase 1 study of AT-301, a nasal spray being developed for the potential treatment of COVID-19, has been enrolled and dosed. More news on: Atossa Therapeutics, Inc., Healthcare stocks ...
SEATTLE, Aug. 17, 2020 (GLOBE NEWSWIRE) -- Atossa Therapeutics, Inc. (Nasdaq: ATOS), a clinical-stage biopharmaceutical company seeking to discover and develop innovative medicines in areas of significant unmet medical need with a current focus on breast cancer and COVID-19, today announced...
Atossa Therapeutics (NASDAQ: ATOS ) : Q2 GAAP EPS of -$0.43 misses by $0.15 . More news on: Atossa Therapeutics, Inc., Earnings news and commentary, Healthcare stocks news, , Read more ...
SEATTLE, Aug. 13, 2020 (GLOBE NEWSWIRE) -- Atossa Therapeutics, Inc. (Nasdaq: ATOS), a clinical-stage biopharmaceutical company seeking to discover and develop innovative medicines in areas of significant unmet medical need with a current focus on breast cancer and COVID-19, today announced...
LOS ANGELES, CA / ACCESSWIRE / August 5, 2020 / LD Micro today announced the initial list of companies slated to present at the upcoming LD 500, taking place September 1st-4th, 2020, exclusively online. "For the first time in ten years, we were unable to host our mid-year conference, which ...
An ethics committee in Australia has signed off on a Phase 1 clinical trial evaluating Atossa Therapeutics' ( ATOS +6.6% ) AT-301, administered via nasal spray, for the potential treatment of patients who have been diagnosed with COVID-19 but are not experiencing symptoms requiring hospi...
SEATTLE, Aug. 03, 2020 (GLOBE NEWSWIRE) -- Atossa Therapeutics, Inc. (NASDAQ: ATOS ), a clinical-stage biopharmaceutical company seeking to discover and develop innovative medicines in areas of significant unmet medical need with a current focus on breast cancer and COVID-19, today anno...
News, Short Squeeze, Breakout and More Instantly...
Atossa Therapeutics Inc. Company Name:
ATOS Stock Symbol:
NASDAQ Market:
Atossa Therapeutics Inc. Website:
SEATTLE, July 22, 2024 (GLOBE NEWSWIRE) -- Atossa Therapeutics, Inc. (Nasdaq: ATOS) (“Atossa” or the “Company”) today announced that the 12-patient 80mg pharmacokinetic (PK) run-in cohort of the Phase 2 EVANGELINE (Endoxifen Versus exemestANe GosEreLIn) study has fully...